Xenopus oocytes are arrested in prophase of the first meiotic division. In response to progesterone, they re-enter meiosis and arrest again in metaphase of the second meiotic division. This process, called meiotic maturation, is under the control of the Cyclin B-Cdc2 complex, M phase promoting factor (MPF). Injection of a constitutively active Xenopus H-Ras protein activates MPF, suggesting that Ras proteins could be implicated in the progesterone transduction pathway. The aim of this study was (1) to elucidate the pathway triggered by H-Ras leading to MPF activation in Xenopus oocytes and (2) to investigate whether endogenous H-Ras is involved in the physiological process of meiotic maturation. We generated three constitutively active double mutants, each of them recruiting a single effector in mammalian cells, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) or RalGDS. Our results show that the activation of a PI3K-related enzyme is crucial for H-Ras-induced MPF activation, whereas the recruitment of either MAPK or RalGDS is not. However, although the H-Ras/PI3K pathway is functional in Xenopus oocytes, it is not the physiological transducer of progesterone responsible for meiotic resumption.
Introduction
Xenopus full-grown oocytes are naturally arrested in prophase of the first meiotic division (prophase I). The release from this prophase block is triggered by progesterone. The Cyclin B-Cdc2 complex, M phase promoting factor (MPF), is activated 4-6 h after hormonal stimulation and induces the transition between prophase I and metaphase II, called meiotic maturation (reviewed by Karaiskou et al., 2001; Perdiguero and Nebreda, 2004) . In prophase oocytes, MPF is maintained inactive by inhibitory phosphorylations of its catalytic subunit Cdc2 on Thr14 and Tyr15 (Gautier et al., 1988 (Gautier et al., , 1989 . Therefore, MPF activation relies on a double dephosphorylation catalysed by the Cdc25 phosphatase (Dunphy and Kumagai, 1991; Gautier et al., 1991) . The pathway triggered by progesterone and leading to MPF activation depends on a drop in cyclic AMP (cAMP) concentration and the subsequent downregulation of cAMP-dependent protein kinase (PKA) (Maller and Krebs, 1977; Wang and Liu, 2004 ). This event is followed by the synthesis of new proteins from maternal mRNAs that are necessary for MPF activation. Among the proteins synthesized in response to hormonal stimulation are B-type Cyclins and the product of the c-mos proto-oncogene (Sagata et al., 1988; Kobayashi et al., 1991) . Mos is a kinase that activates the mitogen-activated protein (MAP) kinase kinase, MEK1, which in turn activates the MAP Kinase (MAPK) (reviewed by Castro et al., 2001) . High levels of MAPK activity that can be induced by injecting several MAPK activators in oocytes are sufficient to trigger Cdc2 activation (Sagata et al., 1989; Muslin et al., 1993; Haccard et al., 1995; Huang et al., 1995) . However, neither the Mos/MAPK pathway nor the synthesis of Cyclins is necessary for MPF activation (Fisher et al., 2000; Gross et al., 2000; Hochegger et al., 2001; Dupre´et al., 2002a) , but the simultaneous inhibition of both pathways inhibits progesteroneinduced meiotic maturation (Haccard and Jessus, 2006) .
It is established that the cAMP decrease depends upon an inhibition of adenylate cyclase. However, the molecular connection between this enzyme and the steroid hormone has not yet been determined. Furthermore, the nature of the progesterone receptor and the implication of trimeric G proteins are also a matter of debate (Bayaa et al., 2000; Tian et al., 2000; Zhu et al., 2003; Liu et al., 2005a) . It has been proposed that small GTPases from the Ras family also participate in the progesterone transduction pathway (Jessus et al., 1998) . H-Ras is present in prophase-arrested Xenopus oocytes, and the microinjection of a constitutively active form of human or Xenopus H-Ras (H-RasV12) induces germinal vesicle breakdown (GVBD) as progesterone does (Birchmeier et al., 1985; Dupre´et al., 2002b) . The goals of this study were (1) to determine whether H-Ras is physiologically implicated in progesterone-induced meiotic maturation and (2) to identify the target(s) of H-Ras responsible for MPF activation in Xenopus oocytes. Indeed H-Ras is known to activate three major pathways in mammalian cells: Raf/MAPK, RalGDS/ Ral, and phosphatidylinositol 3-kinase (PI3K)/Akt pathways (White et al., 1995) . In oocytes, Raf is phosphorylated and activated during maturation (Galaktionov et al., 1995) , suggesting that progesterone could recruit the Ras/Raf/MAPK pathway for MPF activation (reviewed by Jessus et al., 1998) . Whether the PI3K/Akt or RalGDS/Ral pathway is implicated in Cdc2-Cyclin B activation induced by progesterone or Ras remains to be explored.
To address both questions, we generated three constitutively active double mutants derived from Xenopus H-Ras. In mammalian cells, those double mutants, described as H-RasV12S35, H-RasV12G37 and H-RasV12C40, activate, respectively, each of the three different pathways: Raf/MAPK, RalGDS and PI3K pathways (White et al., 1995) . By microinjecting the different recombinant proteins or their encoding mRNAs into Xenopus oocytes, we show that H-Ras induces Cdc2 activation independently of RalGDS and MAPK pathways. Our data further suggest a possible implication of a PI3K family member. However, neither H-Ras nor the PI3K pathway is required for progesterone-induced meiotic maturation under physiological conditions.
Results

XeH-RasV12G37 induces GVBD and activation of Cdc2
We recently showed that injecting a constitutively active form of Xenopus H-RasV12 (XeH-RasV12) in Xenopus oocytes induces Cdc2-Cyclin B activation and meiotic resumption (Dupre´et al., 2002b) . To further investigate which of the H-Ras effectors accounts for XeH-RasV12 effects in oocytes, three constitutively active double mutants of XeH-Ras were produced, XeH-RasV12S35, XeH-RasV12G37 and XeH-RasV12C40, expected to selectively activate the Raf/MAPK pathway, RalGDS and PI3K, respectively (White et al., 1995) .
Identical amounts of recombinant proteins or their mRNAs were injected into prophase oocytes and GVBD was monitored to assess the ability of these mutants to induce meiotic maturation (Figure 1 ). Only XeHRasV12G37 double mutant induced GVBD (Figure 1a and d), albeit with a slower time course when compared to progesterone or XeH-RasV12 (Figure 1a ). Identical amounts of XeH-RasV12S35 and XeH-RasV12C40 proteins or mRNAs did not induce meiotic maturation even 24 h after injection (Figure 1 ). To ascertain that GVBD was correlated with MPF activation, Cdc2 activity was assayed by measuring histone H1 phosphorylation in vitro or by detecting the Tyr15 phosphorylation status of Cdc2 by Western blot and also by monitoring the electrophoretic retardation of Cyclin B2 migration. After progesterone treatment or injection of XeH-RasV12 and XeH-RasV12G37, Cdc2 kinase and MAPK were activated and Mos was synthesized (Figure 1b and d) . Injection of XeHRasV12S35 or XeH-RasV12C40 did not induce GVBD and did not activate Cdc2 as well. Hence, among the three double mutants, only XeH-RasV12G37 induces GVBD and the main biochemical hallmarks of meiotic maturation.
All XeH-RasV12 mutant forms are prenylated As neither XeH-RasV12C40 nor XeH-RasV12S35 induced MPF activation (Figure 1 ), we ascertained whether these proteins were prenylated in oocytes. This modification, required to target Ras to membranes, is accompanied by an increased solubility of the protein in a Triton X-114 phase and can be measured by phase-partitioning (Bordier, 1981) . As shown in Figure 2 , all recombinant XeH-Ras proteins were recovered as a function of time in the Triton X-114 phase indicating that the inability of XeH-RasV12S35 Oocytes were homogenized at GVBD time or 12 h after injection when GVBD did not occur. Extracts were immunoblotted with anti-Cyclin B2, anti-P-MAPK and anti-P-Tyr-Cdc2 antibodies. The occurrence or absence of GVBD after 18 h is indicated by þ or À.
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XeH-RasV12S35 can activate the Raf/MAPK pathway We then wondered if XeH-RasV12S35 was functional and able to activate the Raf/MAPK pathway, as its human homologue does in mammalian cells (White et al., 1995) . As newly synthesized Mos is the essential kinase leading to MAPK activation in oocytes (reviewed by Castro et al., 2001) , Mos synthesis was prevented using the protein synthesis inhibitor cycloheximide. Under these conditions, Raf becomes the sole MAPK activator in the oocyte. Although progesterone did not trigger MAPK activation in the presence of cycloheximide, injection of XeH-RasV12 and XeH-RasV12S35 did, albeit partially ( Figure 3a ). XeH-RasV12S35 appeared to be less efficient than the single XeHRasV12 mutant. This might be owing to the second mutation that weakens the activity of the protein. We then increased the amount of available Raf by injecting mRNA encoding Xenopus wild-type Raf. Twelve hours later, Mos synthesis was prevented by adding cycloheximide. As shown in Figure 3a , injection of either XeH-RasV12 or XeH-RasV12S35 induced MAPK phosphorylation more efficiently in the presence of overexpressed Raf. Moreover, the injection of XeRasV12S35 in oocytes overexpressing Raf was able to induce GVBD in the absence of cycloheximide ( Figure 3b ). These results indicate that although XeHRasV12S35 is functional, it requires the overexpression of Raf to generate enough MAPK activity and thus to trigger meiotic maturation.
XeH-RasV12C40 induces GVBD only in the presence of overexpressed PI3K
We next tested the functionality of the XeH-RasV12C40 mutant towards PI3K. Prophase oocytes were injected or not with an mRNA encoding a membrane-targeted form of PI3K (rCD2p110) (Reif et al., 1996) . After 12 h, XeH-RasV12C40 was injected or progesterone was added. Neither XeH-RasV12C40 nor rCD2p110 alone induced GVBD (Figure 4) . However, these two mutants together induced GVBD, and Cdc2 and MAPK activation. Under this condition, GVBD was totally inhibited by LY294002 (Figure 4 ), a pharmacological inhibitor of PI3Ks. This inhibitor was unable to block progesteroneinduced maturation. Therefore, a membrane-targeted mutant of PI3K is not sufficient per se to induce meiotic maturation, unless it is activated by XeH-RasV12C40.
RalGDS and XeRalB do not affect meiotic maturation induced by XeH-RasV12G37
In mammalian cells, H-RasV12G37 preferentially activates the RalGDS pathway (White et al., 1995) . We investigated the contribution of this pathway in Cdc2 (a) Prophase oocytes (Pro) were injected or not with an mRNA encoding wild-type Raf. Twelve hours later, oocytes were incubated with cycloheximide (CHX), 1 h later progesterone (Pg) was added or RasV12 or RasV12S35 injected. Twelve hours later, oocytes were homogenized and extracts were immunoblotted with anti-Raf, anti-extracellular-regulated kinase-1 (ERK-1) and anti-P-MAPK antibodies. (b) Prophase oocytes were injected or not with an mRNA encoding wild-type Raf. Twelve hours later oocytes were stimulated with progesterone or microinjected with RasV12 or RasV12S35 recombinant proteins. GVBD was scored 18 h later, and oocytes were homogenized at GVBD time or at the end of the experiment when GVBD did not occur. Extracts were immunoblotted with anti-Raf, anti-Cyclin B2 and anti-P-MAPK antibodies. A new signaling pathway for Ras in Xenopus oocyte M Gaffré et al activation. As no RalGDS dominant negative mutant has been described yet, we used the RalS28N dominant negative mutant known to bind and to trap RalGDS, preventing the activation of all the RalGDS effectors (Urano et al., 1996) . Oocytes were injected with XeRalBS28N or XeRalBG23V, two forms of RalB, respectively, shown to be dominant negative and constitutively active in Xenopus (Lebreton et al., 2004) . Although RalB mutant proteins were expressed at high levels, they neither induced meiotic maturation nor affected GVBD time course after progesterone treatment or after the microinjection of recombinant XeH-RasV12G37 ( Figure 5 ). These results indicate that the RalGDS pathway is not involved in MPF activation triggered by either progesterone or XeH-RasV12G37.
XeH-RasV12G37 activates Cdc2 independently of the MAPK pathway
We therefore investigated whether this mutant signals through another pathway. To test the dependency on MAPK, its activation was inhibited by incubating oocytes with the MEK inhibitor U0126. Under these conditions, oocytes underwent GVBD and MPF was activated in response to progesterone treatment, XeHRasV12 or XeH-RasV12G37 injection even though MAPK remained in its inactive unphosphorylated form (Figure 6a and b) . Next, we used the CDK inhibitor p21
Cip1
, which specifically binds and inhibits Cdc2 in ovo (FrankVaillant et al., 1999) . Following p21
Cip1 injection, oocytes were incubated in the presence of progesterone or microinjected with either XeH-RasV12 or XeHRasV12G37. P21
Cip1 efficiently prevented GVBD, Cdc2 activation and Mos synthesis in all cases (Figure 6c) .
A partial activation of MAPK was observed in response to the injection of XeH-RasV12, despite the absence of Mos, reflecting the activation of Raf, as reported previously (Dupre´et al., 2002b) (Figure 6c ). However, Figure 4 RasV12C40 induces meiotic maturation in the presence of a membrane-targeted PI3K. Prophase (Pro) oocytes were incubated or not with LY294002. One hour later, mRNA encoding rCD2p110 was injected or not. Twelve hours later, oocytes were injected with RasV12C40 or stimulated with progesterone. GVBD was scored 18 h later and oocytes were homogenized at GVBD time or at the end of the experiment. Extracts were immunoblotted with anti-Cyclin B2 and anti-P-MAPK antibodies. Oocytes were homogenized at the time of GVBD or 24 h after injection when GVBD did not occur. Extracts were immunoblotted with anti-Cyclin B2 and anti-RalB antibodies. (c) Prophase oocytes were injected with mRNA encoding RalBG23V or RalBS28N. Twelve hours later, oocytes were microinjected or not with RasV12G37 recombinant protein and GVBD time course was monitored. (d) Oocytes were homogenized at the time of GVBD, or 24 h after RalB injection when GVBD did not occur. Extracts were immunoblotted with anti-Cyclin B2, anti-RalB and anti-P-Tyr Cdc2 antibodies.
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XeH-RasV12G37 protein did not induce MAPK activation in p21
Cip1 -injected oocytes (Figure 6c ), meaning that this mutant does not recruit the Raf/MAPK pathway in Xenopus oocyte. Therefore, MAPK activation observed in response to XeH-RasV12G37 is solely the consequence of Mos synthesis occurring downstream of Cdc2. Altogether, these results indicate that XeH-RasV12G37 activates Cdc2 through an MAPKindependent pathway.
Cdc2 activation induced by H-RasV12G37 is sensitive to LY294002
To investigate the possible implication of a PI3K downstream of XeH-RasV12G37, prophase oocytes were incubated in the presence of LY294002 before XeH-RasV12 injection or progesterone incubation. Both treatments induced GVBD, MAPK and MPF activation in the presence of LY294002, albeit with a retarded time course (Figure 7 ). This result argues that PI3Ks do not play an essential role in progesterone-or XeH-RasV12-induced meiotic maturation. Surprisingly, LY294002 totally prevented GVBD and Cdc2 activation in XeH-RasV12G37-injected oocytes (Figure 7) . Similar results were obtained using another PI3K inhibitor, wortmannin (data not shown). Therefore, a target of LY294002 and wortmannin, possibly a PI3K family member, is unexpectedly required for meiotic maturation induced by XeH-RasV12G37 injection.
Insulin-and progesterone-induced maturation is independent of H-Ras
A crucial unanswered and controversial question was whether endogenous H-Ras proteins could be involved in the physiological process of maturation. We took advantage of a recombinant H-Ras mutated on Ser17 (XeH-RasN17), which blocks the action of endogenous Cip1 injection when GVBD did not occur. Extracts were immunoblotted with anti-Cyclin B2, anti-P-Tyr Cdc2, anti-Mos, anti-ERK-1 and anti-P-MAPK antibodies. In (a-c), GVBD was scored after 18 h and is indicated as þ or À. H-Ras in cultured cells (Stacey et al., 1991) . When injected into prophase oocyte, this mutant totally blocked meiotic maturation and, MPF and MAPK activation induced by XeH-RasV12 injection (Figure 8 ), indicating that XeH-RasN17 exerts in ovo a dominant negative effect on XeH-RasV12. However, XeHRasN17 did not significantly alter progesterone-or insulin-induced meiotic maturation and both Cdc2 and MAPK were activated. These results bring new evidence of a non-essential role for endogenous H-Ras in meiosis resumption induced by progesterone or insulin in Xenopus oocytes.
Discussion
The purpose of the present work was to identify the pathway downstream of H-Ras and leading to Cdc2 activation in Xenopus oocytes. Previous studies in Xenopus oocytes were based on mammalian Ras proteins (reviewed by Jessus et al., 1998) . Here we chose to use constitutively active mutants of Xenopus H-Ras. Three classical effector loop mutations were generated in Xenopus H-Ras (White et al., 1995; Peyssonnaux et al., 2000) . Only XeH-RasV12G37 was able to induce Cdc2 activation and meiotic maturation when injected into prophase oocytes.
The Ras/Raf/MAPK pathway It has been thought for many years that the overexpression of mammalian H-Ras mediates its effects through the Raf/MAPK pathway when injected in Xenopus oocytes (Jessus et al., 1998) . In a recent paper, we showed that the active GTP-bound form of XeH-Ras activates Cdc2 independently of the Mos/MAPK pathway (Dupre´et al., 2002b) . We therefore injected XeHRasV12S35 in Xenopus oocytes to specifically study the Raf/MAPK pathway downstream of H-Ras. MPF was not activated upon injection of this mutant unless XeRaf was overexpressed, in agreement with the fact that only high levels of MAPK activity lead to MPF activation (Sagata et al., 1989; Muslin et al., 1993; Haccard et al., 1995; Huang et al., 1995) . Meanwhile, XeH-RasV12 and XeH-RasV12G37 retained the ability to induce GVBD in the presence of U0126 (see Figure 6 ; Dupre´et al., 2002b) showing that they act independently of MAPK.
Activation of MAPK in oocyte: Mos versus Raf MAPK phosphorylation induced in vivo by either XeHRasV12 or XeH-RasV12S35 is always lower in the absence of Mos, indicating that the activation of MAPK by Raf recruitment appears less efficient than the one promoted by Mos. This could be explained by the absence of a proper Raf scaffold or by its specific inhibition in germ cells. It is not surprising that the Ras/ Raf pathway would be silenced in oocytes, which developed a specific MAPK activation system under the control of Mos. This germ cell protein allows a full and sustained activity of MAPK, necessary for oocytes to arrest at metaphase II (Dupre´et al., 2002a) . Nevertheless, active MAPK is not required for Cdc2 activation in Xenopus oocytes, neither activated by the Ras/Raf system nor by the endogenous Mos system.
The Ras/RalGDS pathway
The ability of XeH-RasV12G37 to induce Cdc2 activation prompted us to investigate the role of the RalGDS pathway. The injection of a dominant negative form of RalB that blocks RalGDS function did not affect meiotic maturation induced by either XeH-RasV12 (data not shown) or XeH-RasV12G37. On the other hand, the injection of the constitutively active form of RalB did not induce meiotic maturation. Therefore, in Xenopus oocytes, XeH-RasV12G37 does not target the RalGDS/Ral pathway.
The Ras/PI3K pathway As the pathway downstream of XeH-Ras does not require MAPK or RalGDS, we analysed the possible involvement of a PI3K. We show that Cdc2 activation induced by XeH-RasV12G37 was totally blocked by two pharmacological PI3K inhibitors, LY294002 and wortmannin. On the other hand, XeH-RasV12C40 mutant did not induce GVBD, although this mutant is functional: when injected in oocytes overexpressing a membrane-targeted form of the PI3K catalytic subunit p110a, it triggers meiotic maturation in an LY294002 dependent manner.
Therefore, XeH-RasV12G37 induces Cdc2 activation through a PI3K-related enzyme in Xenopus oocytes as shown in other cell types and species (RodriguezViciana et al., 1996; Pacold et al., 2000; Prober and Edgar, 2002) . Furthermore, the PI3K enzyme targeted by XeH-RasV12G37 in Xenopus oocytes must be different from the one that could be activated by XeHRasV12C40, as shown for mast cells (Kinashi et al., 2000) . Noteworthy, PI3K inhibitors have been recently shown to also inhibit the human Polo kinase in breast cancer cells (Liu et al., 2005b) . Xenopus Polo (Plx1) is required for Cdc2 activation in Xenopus oocytes (Kumagai and Dunphy, 1996; Abrieu et al., 1997; Karaiskou et al., 1999) . As these inhibitors only delay Cdc2 activation induced by progesterone or XeHRasV12, this suggests that they do not target Plx1 in Xenopus.
In starfish oocytes, the physiological meioticstimulating hormone, 1-methyladenine, induces the resumption of meiosis through the activation of the phosphoinositide-dependent kinase1 (PDK1)/Akt pathway (Hiraoka et al., 2004) . Such PI3K/Akt pathway may also trigger MPF activation in Xenopus oocytes in response to XeH-RasV12G37, a hypothesis supported by the fact that the injection of Akt induces maturation (Andersen et al., 1998) .
Physiological implication of XeH-Ras in meiotic resumption
Altogether, our results show that XeH-Ras induces Cdc2 activation through a new target, possibly a PI3K. A major remaining question is whether endogenous XeH-Ras represents a physiological link between hormonal stimulation and Cdc2 activation. In this study, we show that resumption of meiosis induced by progesterone is not affected by the inhibition of each of the three main effectors of H-Ras, PI3K, RalGDS and MAPK. It is also insensitive to XeH-RasN17, whereas this mutant efficiently blocks maturation induced by XeH-RasV12. We then conclude that H-Ras is not physiologically necessary for the resumption of meiosis, although we cannot exclude that it could participate in this process.
Materials and methods
Materials
Xenopus laevis adult females (CNRS, Rennes, France) were bred and maintained under laboratory conditions. Reagents, unless otherwise specified, were from Sigma-Aldrich Chimie S.a.r.l, Lyon, France.
Xenopus oocytes treatments Xenopus oocytes were isolated and prepared as described by Jessus et al. (1991) . Oocytes were microinjected with 50 nl of the bacterial recombinant proteins adjusted to 0.75 mg/ml or mRNAs adjusted to 1 mg/ml. Oocytes were incubated in the presence of 1 mM progesterone, 5 mM insulin, 50 mM U0126 (Promega France, Charbonnie`res, France), 30 mM LY294002 (Cell Signaling, Danvers, USA) or 100 mg/ml cycloheximide. Oocyte maturation was monitored following the appearance of a white spot at the animal pole.
Xenopus oocyte extracts Oocytes were homogenized at 41C in 10 ml/oocyte in 80 mM bglycerophosphate, pH 7.3, 20 mM ethylene glycol tetraacetate, 15 mM MgCl 2 , 1mM dithiothreitol and protease inhibitor cocktail (P-8340). Lysates were centrifuged at 15 000 g at 41C for 15 min, and the supernatants were collected and analysed. The Triton X-114 extraction procedure was described by Dupre´et al. (2002b) .
Mutagenesis of XeH-Ras
Xenopus H-Ras mutants were constructed using site-directed mutagenesis by double PCR reactions (Higuchi et al., 1988) . The first PCR reaction was performed using mutagenic primers complementary to each other and a pair of outer primers with XeH-RasV12 (Dupre´et al., 2002b) as a template for XeH-RasV12S35, XeH-RasV12G37 and XeH-RasV12C40 and XeH-Ras as a template for XeH-RasN17. Full-length double XeH-Ras mutants were made by second PCR reaction combining two PCR products from the first reactions and the outer primers.
Purification of bacterially expressed recombinant proteins p21
Cip1 and all XeH-Ras proteins were purified as described (Frank-Vaillant et al., 1999; Dupre´et al., 2002b) .
mRNA synthesis XeH-RasV12, XeH-RasV12G37, XeH-RasV12S35 and XeHRasV12C40 in pUH25-2 and rCD2p110 in pcDNA3 (a kind gift from A Hall; Reif et al., 1996) were amplified by PCR and a T7 promoter was added. mRNAs were synthesized using the T7 mMESSAGE MACHINE kit (Ambion Europe Ltd., Cambridgeshire, UK). mRNAs from pRN3 plasmids containing XeRalBG23V and XeRalBS28N (a kind gift from J Moreau; Lebreton et al., 2004) and from pBluescript KS plasmid containing XeRaf (a kind gift from M Philippe; Le Guellec et al., 1991) were synthesized using the T3 kit.
Western blotting
Samples (equivalent to one or two oocytes) were electrophoresed on 10% Anderson (Anderson et al., 1973) or 12% (Amresco, Solon, OH, USA) SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Schleicher and Schuell). The following antibodies were used: anti-Cyclin B2 (Gautier et al., 1990; De Smedt et al., 2002) ; anti-Ras (BD Transduction Laboratories France, Le-Pont-deChaix, France); anti-P-MAPK and anti-P-Tyr15 Cdc2 (Cell Signaling); anti-ERK-1, anti-Raf, anti-Mos and anti-RalB (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). The secondary horseradish peroxidase-conjugated antibodies were from Jackson Immunoresearch, West Grove, USA and were detected by chemiluminescence (Perkin-Elmer Life Sciences France, Courtaboeuf, France).
Kinase assays
Histone H1 kinase assays were performed on p13-Sepharosebound extracts (three oocytes equivalent) in the presence of [g-32 P]ATP (MP Biomedicals, Illkirch, France, 0.1 mCi/assay), 100 mM ATP and 0.5 mg/ml histone H1 (Roche-Paris, Neuilly/ Seine, France) according to Jessus et al. (1991) .
Reproducibility
The results presented are representative of experiments repeated at least three times using each time a different frog.
